Access news

This section is dedicated to updates on access to lymphoma drugs in Europe, as well as to studies and initiatives that help better understand or improve the access to safe, efficient and supportive lymphoma care in Europe.


Country Access News

France Lymphoma Espoir currently participates in the evaluation of Ledaga (chormethine), approved by the EMA in December 2016 for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma. 

On 9 May the Lymphoma Association (UK) acknowledged with relief NICE recommendation for funding of brentuximab vedotin for adult patients with CD30+ relapsed/refractory Hodgkin Lymphoma.


Country Funding Systems

On 31 May the Belgian Health Care Knowledge Center published a very informative report on the Belgian process for Managed Entry Agreements (MEA), which analyses both the Belgian and the European experience. MEA are alternative funding mechanisms aimed at enabling early access to pharmaceuticals, whose (cost-)effectiveness is still unknown or for which the budget impact is expected to be very high.

A study published on 27 April 2017 in the Annals of Oncology analyses the value delivered to society by the NHS Cancer Drugs Fund (CDF), which was established in 2010 to reduce delays and improve access to cancer drugs in England.


European Care Cooperation

EuroBloodNet is the European Reference Network (ERN) on rare hematological conditions. It brings together 66 highly specialised hospital centres from 15 EU countries with expertise on malignant and non-malignant blood diseases. LCE works in close cooperation with Pierre Aumont, who represents patients with Lymphoid malignancies in the network governance system. On 22 June Prof. Pierre Fenaux, EuroBloodNet Coordinator, will present the Network to the patient organisations participating in EHA 2017 Congress in Madrid.



On 15 May, the European Commission published the results of the online consultation on “Strengthening of the EU cooperation on Health Technology Assessment (HTA)”. Most patient organisations expressed their preference for a common clinical and economical evaluation of health technologies (full joint HTA). Based on the results of this consultation, the European Commission is now expected to present a legislative proposal on the future of EU cooperation on HTA.


Global Database Search

 knowyoursubtype iconb   facebook2 twitter2 youtube1




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 05/30/17. Copyright © 2017 Lymphoma Coalition. All rights reserved.